Why hasn't AMRN jumped on this for the US market ? My guess is that they know the FDA will want an independent clinical trial with US patients . Minimum would be for the Marine indication ...TG's over 500mg/dl . So if AMRN was to start tomorrow on this , we are probably looking at 2 yrs from start of trial to final FDA approval for VHTG's ( Marine indication ) and that would really eat into the Cash on Hand .
To then get insurers coverage ( after FDA approval ) the once a day pill would need to price at or below the current generic price for 4 caps of the existing . Which it might be able to do ...but a tell would be the pricing in Japan . What does the new once daily pill cost compared the the old Epadel in Japan ...and how much are they selling ?